incretin hormone glp-1 Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Incretin hormones and obesity -

Type 2 Diabetes Prevalence and Etiology T2D is a common metabolic disorder characterized by major dysregulations in glucose homeostasis

Tirzepatide remains an outstanding, first-line agent for patients focused on achieving robust weight loss while mitigating the risk of Type 2 Diabetes

(31) Discussion The findings from this literature review suggest that GLP-1 receptor agonists influence bone metabolism, wound healing, and surgical outcomes, with both preclinical and clinical evidence supporting potential benefits in orthopedic settings

Akhondzadeh, S., Mostafavi, S

The recommended intake is 8.7 mg daily for men and 14.8 mg for women

Consult Your Doctor if Symptoms Persist If side effects like nausea, vomiting, or diarrhoea persist for more than a few weeks, its important to consult your healthcare provider